Targets › VDR
23 programs from 23 companies in 49 trials: 16 Phase 2, 15 Phase 3, 11 Phase 4, 7 Phase 1; Other, Oncology, Immunology; next expected readout Nov 2026.
Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells. Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR. The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes. (UniProt, P11473)
Open in Phaseline: the race on VDR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chulalongkorn University | Calcitriol Vitamin D receptor agonist | VDR | Phase 4 | Cholestatic Liver Disease | Nov 2026 |
| University of Texas Southwestern Medical Center | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 4 | Sarcoidosis | Dec 2026 |
| Zhejiang Provincial People's Hospital | Eldecalcitol Vitamin D receptor agonist | VDR | Phase 4 | Sarcopenia | May 2027 |
| RDC Clinical | Cholecalciferol Vitamin D receptor agonist | VDR | Phase 4 | Healthy Volunteer; COVID-19; Bronchiectasis; Osteoarthritis … | Sep 2027 |
| Nishtar Medical University | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 4 | Pre-eclampsia | – |
| Riphah International University | Intralesional Vitamin D3 Vitamin D3 receptor agonist with immunomodulatory properties | VDR | Phase 4 | Viral Wart | – |
| Sengkang General Hospital | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 3 | Sarcopenia | Dec 2026 |
| Ottawa Hospital Research Institute | Vitamin D3 Drops Vitamin D receptor agonist; 1,000-10,000 units daily based on serum levels | VDR | Phase 3 | Lung Cancer | Dec 2028 |
| University of Rochester | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 3 | Stage I Prostate Cancer AJCC v8 | Apr 2029 |
| Ain Shams University | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 3 | Corrosive Injury | – |
| Sohag University | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 3 | Scar, Hypertrophic | – |
| Ghufran Dhari Awad | Calcitriol Vitamin D receptor agonist | VDR | Phase 2 | Accelerated Orthodontic Tooth Movement | Dec 2026 |
| University of Arizona | Calcipotriene Vitamin D receptor agonist | VDR | Phase 2 | Actinic Keratosis | Feb 2027 |
| University of Washington | Calcitriol Vitamin D receptor agonist | VDR | Phase 2 | Kidney Failure, Chronic | Feb 2027 |
| OPKO Health | Calcifediol (CTAP101) Vitamin D receptor agonist | VDR | Phase 2 | CKD Stage 3 | Oct 2027 |
| University of Ioannina | Alphacalcidol Vitamin D receptor agonist (active vitamin D metabolite) | VDR | Phase 2 | Scoliosis; Adolescence | – |
| Alexandria University | Calcipotriene Vitamin D receptor agonist | VDR | Phase 2 | Oral Leukoplakia | – |
| Northwell Health | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 2 | Graves Disease | – |
| Abramson Cancer Center at Penn Medicine | paricalcitol Vitamin D receptor agonist | VDR | Phase 1 | Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy | Dec 2026 |
| Aga Khan University | Ergocalciferol Vitamin D receptor agonist | VDR | Phase 1 | Anovulatory Infertility | Dec 2026 |
| University of Alabama at Birmingham | Vitamin D supplementation Vitamin D receptor activation; micronutrient supplementation | VDR | Phase 1 | Prematurity; Extreme | May 2027 |
| Melissa Pugliano-Mauro | Calcipotriene Vitamin D receptor agonist | VDR | Phase 1 | Carcinoma, Squamous Cell | Sep 2027 |
| Foundation University Islamabad | 1,25 DHC injection Active vitamin D3 (1,25-dihydroxycholecalciferol) - stimulates bone remodeling and osteocl | VDR | Phase 1 | Malocclusion of Anterior Teeth | Dec 2027 |
Sarcopenia (2) COVID-19 (2) Obesity, Childhood (2) Asthma (2) Corrosive Injury (1) Anovulatory Infertility (1) Lung Cancer (1) Graves Disease (1) Accelerated Orthodontic Tooth Movement (1) Healthy Volunteer (1) Bronchiectasis (1) Osteoarthritis (1)
small molecule (19)
Ain Shams University (1) Aga Khan University (1) Ottawa Hospital Research Institute (1) Zhejiang Provincial People's Hospital (1) Northwell Health (1) Ghufran Dhari Awad (1) RDC Clinical (1) Alexandria University (1) University of Washington (1) University of Alabama at Birmingham (1) Foundation University Islamabad (1) University of Ioannina (1) Sohag University (1) University of Arizona (1) Chulalongkorn University (1) Nishtar Medical University (1) Melissa Pugliano-Mauro (1) OPKO Health (1) Riphah International University (1) University of Rochester (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.